REGENXBIO Prices $100M Offering at $9.00/Share, a 20% Discount to Market
RGNX sits 86% above its 52-week low of $5.455 on elevated volume (3.6× avg).
Summary
REGENXBIO priced a $100M equity offering at $9.00/share, a 20% discount to market, raising ~$94M to fund operations into Q2 2027. The deep discount and dilution pressure existing shareholders.
Key Events · Financing and Capital Events · RGNX
-
$100M Offering Priced at Deep Discount
10,003,889 shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999, a 20% discount to the July 16 close of $11.20. Underwriters have a 30-day option for 1,667,250 additional shares.
-
Net Proceeds of ~$94M Extend Runway
After fees, REGENXBIO expects ~$93.7M (or ~$107.8M if the option is exercised). Combined with the $100M AbbVie milestone, cash is sufficient into Q2 2027.
-
Immediate Dilution of ~18%
Pro forma shares outstanding rise to ~61.6M (or ~64.4M with option and warrant exercise), diluting existing holders by roughly 18%. Net tangible book value per share increases to $1.86 from $0.41.
-
Going Concern Risk Remains
The company reiterates substantial doubt about its ability to continue as a going concern. The offering buys time but does not resolve the underlying cash burn.
Analysis · RGNX · Life Sciences
REGENXBIO priced a $100 million common stock and pre-funded warrant offering at $9.00 per share, a steep 20% discount to yesterday's close of $11.20. The deal includes 10 million shares and 1.1 million pre-funded warrants, with an underwriter option for 1.67 million more shares. Net proceeds of ~$94 million extend the cash runway into Q2 2027, but the deep discount signals weak demand and dilutes existing holders by roughly 18% (pro forma). This follows a preliminary filing yesterday and comes amid going concern doubts, though recent positive pipeline news (RGX-202 Phase III data, AbbVie milestone) provides a backdrop.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGNX was trading at $10.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $511.3M. The 52-week trading range was $5.46 to $16.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.